RE:RE:RE:RVX NEW POST BLOG
wayne, it is bizarre but consistent with this bizarre MB that no one bothered to help you out:
directly from a March 19, 2015 interview:
“For 2015, we are most excited about completing the planning of a Phase III clinical trial for RVX-208 in which we will evaluate the drug’s ability to reduce major adverse cardiac events (MACE) such as heart attacks and strokes in patients with established CVD and diabetes mellitus and low HDL,” McCaffrey told BioSpace. ..."
I conclude from this that RVX is expecting to dose its first patient (ie actually start the trial) in 2016 and IMO all action and activity before the first dosing is "planning" this would include gaining approval to proceed, contracting with a CRO, contracting with sites, etc., etc. hope this helps..